Ignite Creation Date:
2024-05-06 @ 1:35 AM
Last Modification Date:
2024-10-26 @ 11:06 AM
Study NCT ID:
NCT01842646
Status:
COMPLETED
Last Update Posted:
2021-06-14
First Post:
2013-04-25
Brief Title:
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome MDS
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase II Study Evaluating the Oral Smoothened Inhibitor PF-04449913 in Patients With Myelodysplastic Syndrome MDS
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being done to see how safe an investigational drug is and test how well it will work to help people with refractoryrelapsed myelodysplastic syndrome MDS or chronic myelomonocytic leukemia CMML
Detailed Description:
The main purpose of this study is to see whether the participants disease responds favorably to the investigational drug PF-04449913
Post treatment Phase After coming off of active treatment study drug PF-04449913 participants will be followed monthly for survival only No other data will be captured during this time
Post treatment Phase After coming off of active treatment study drug PF-04449913 participants will be followed monthly for survival only No other data will be captured during this time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None